CHU de Nîmes
Nîmes, 30029, France
NCT Number: NCT05075798
Transthyretin amyloidosis (aTTR) initially described as a rare disease, became the most serious hereditary polyneuropathy of adult onset and family screening has made it possible to identify and follow up many asymptomatic patients and carriers of the mutation in the TTR gene.
Considered as a systemic disease with involvement of target organs (the heart, the eye, the kidney and peripheral nervous system), it seems to be more complex for neurologists according to recent publications raising the issue of central nervous system involvement.
Indeed, TTR amyloid deposits seem to be correlated with the duration of the disease. These deposits can cause cortical damage by different mechanisms: direct TTR toxicity or as a result of pathology related to cerebral amyloid angiopathy (intraparenchymal or subarachnoid hematomas, small infarcts, hemosiderin). A small number of mutations in the TTR gene cause a rare phenotype of systemic amyloidosis, the oculoleptomeningeal form, characterized by clinical neurological symptoms: progressive dementia, epilepsy, ataxia, spastic paraparesis, stroke-like episodes.
Hypothesis of the work: the central nervous system involvement is probably underestimated on the radiological description in patients with TTR mutation.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Nîmes, 30029, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
pure observational study
Time frame: Baseline
Presence of signs of chronic bleeding on brain MRI (Yes/No)
Centre Hospitalier Universitaire de Nīmes
Other
A Comprehensive Retrospective Study of Cerebral MRI Anomalies in Mutated Transthyretin Amyloidosis Patients
Acronym: TTR-SNC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05023889
Amyloid Neuropathies, Amyloid Neuropathies, Familial
Austin, Texas, United States
View Trial DetailsNCT03588468
Amyloid Neuropathies, Amyloidosis
Marseille, PACA, France
View Trial DetailsNCT03431896
AL Amyloidosis, Alzheimer Disease
Cleveland, Ohio, United States
View Trial DetailsNCT03759379
Amyloidosis, Amyloidosis, Familial
La Mesa, California, United States
View Trial Details